title: [Epidemiological, clinical and prognostic aspects of cryptococcal meningitis in hospital area of Bamako, Mali].
abstract: The cryptococcosis is a major mycosis of forecast holds during the AIDS. The objective of this study was to determine the frequency of this affection during the AIDS with the service of the infectious diseases of the teaching hospital of the Point G. On the whole 55 patients reached of AIDS were included in this study. They presented all of the evocative signs of meningitis attack. The analysis of the cerebral spinal fluid (CSF) allowed us to detect among this population 17 cases of cryptococcal meningitis means a frequency of 30.9%. The average age was 34 years with the extreme ones going from 18 to 60 years old. The clinical signs were as follows: disorder of the conscious in 4/17 cases (23.6%), fever in 2/17 cases (11.8%), signs of meningitis in 11/17 cases (64.7%). The CSF was clear as water of rock with a lymphocyte at 100% to all the patients. The examination with the Indian ink noted yeasts in capsular identified like the Cryptococcus ones. The treatment was based on amphotericin B intravenous. Lethality rate was 58.8% in 10/17 cas. The crytococcus constitutes a frequent etiology of the meningo-encephalitis demonstrations during the AIDS in this service. We recommend the search for cryptococcus in front of any sign of meningitis occurring during AIDS in Mali.
authors.affiliation: Faculté de Médecine, de Pharmacie et d'Odontostomatologie, Centre National des Oeuvres Universitaires, Bamako, Mali. alabmai@yahoo.fr
authors.forename: A A
authors.initials: AA
authors.lastname: Oumar
authors.forename: S
authors.initials: S
authors.lastname: Dao
authors.forename: M
authors.initials: M
authors.lastname: Ba
authors.forename: B
authors.initials: B
authors.lastname: Poudiougou
authors.forename: A
authors.initials: A
authors.lastname: Diallo
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003454:Cryptococcus / Q000302:isolation & purification; D006801:Humans; D007275:Injections, Intravenous; D008302:Mali / Q000453:epidemiology; D016919:Meningitis, Cryptococcal / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B